Concomitant targeting of the mTOR/MAPK pathways: Novel therapeutic strategy in subsets of RICTOR/KRAS-altered non-small cell lung cancer

Dennis Ruder, Vassiliki Papadimitrakopoulou, Kazuhiko Shien, Carmen Behrens, Neda Kalhor, Huiqin Chen, Li Shen, J. Jack Lee, Waun Ki Hong, Ximing Tang, Luc Girard, John D. Minna, Lixia Diao, Jing Wang, Barbara Mino, Pamela Villalobos, Jaime Rodriguez-Canales, Nana E. Hanson, James Sun, Vincent MillerJoel Greenbowe, Garrett Frampton, Roy S. Herbst, Veera Baladandayuthapani, Ignacio I. Wistuba, Julie G. Izzo

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Despite a therapeutic paradigm shift into targeted-driven medicinal approaches, resistance to therapy remains a hallmark of lung cancer, driven by biological and molecular diversity. Using genomic and expression data from advanced non-small cell lung cancer (NSCLC) patients enrolled in the BATTLE-2 clinical trial, we identified RICTOR alterations in a subset of lung adenocarcinomas and found RICTOR expression to carry worse overall survival. RICTOR-altered cohort was significantly enriched in KRAS/MAPK axis mutations, suggesting a co-oncogenic driver role in these molecular settings. Using NSCLC cell lines, we showed that, distinctly in KRAS mutant backgrounds, RICTOR blockade impairs malignant properties and generates a compensatory enhanced activation of the MAPK pathway, exposing a unique therapeutic vulnerability. In vitro and in vivo concomitant pharmacologic inhibition of mTORC1/2 and MEK1/2 resulted in synergistic responses of anti-tumor effects. Our study provides evidence of a distinctive therapeutic opportunity in a subset of NSCLC carrying concomitant RICTOR/KRAS alterations.

Original languageEnglish
Pages (from-to)33995-34008
Number of pages14
JournalOncotarget
Volume9
Issue number74
Publication statusPublished - Sep 1 2018
Externally publishedYes

Fingerprint

Non-Small Cell Lung Carcinoma
Biodiversity
Therapeutics
Lung Neoplasms
Clinical Trials
Cell Line
Mutation
Survival
Neoplasms

Keywords

  • KRAS mutation
  • MAPK pathway
  • MTORC2
  • Non-small cell lung cancer
  • RICTOR gene abnormalities

ASJC Scopus subject areas

  • Oncology

Cite this

Ruder, D., Papadimitrakopoulou, V., Shien, K., Behrens, C., Kalhor, N., Chen, H., ... Izzo, J. G. (2018). Concomitant targeting of the mTOR/MAPK pathways: Novel therapeutic strategy in subsets of RICTOR/KRAS-altered non-small cell lung cancer. Oncotarget, 9(74), 33995-34008.

Concomitant targeting of the mTOR/MAPK pathways : Novel therapeutic strategy in subsets of RICTOR/KRAS-altered non-small cell lung cancer. / Ruder, Dennis; Papadimitrakopoulou, Vassiliki; Shien, Kazuhiko; Behrens, Carmen; Kalhor, Neda; Chen, Huiqin; Shen, Li; Jack Lee, J.; Hong, Waun Ki; Tang, Ximing; Girard, Luc; Minna, John D.; Diao, Lixia; Wang, Jing; Mino, Barbara; Villalobos, Pamela; Rodriguez-Canales, Jaime; Hanson, Nana E.; Sun, James; Miller, Vincent; Greenbowe, Joel; Frampton, Garrett; Herbst, Roy S.; Baladandayuthapani, Veera; Wistuba, Ignacio I.; Izzo, Julie G.

In: Oncotarget, Vol. 9, No. 74, 01.09.2018, p. 33995-34008.

Research output: Contribution to journalArticle

Ruder, D, Papadimitrakopoulou, V, Shien, K, Behrens, C, Kalhor, N, Chen, H, Shen, L, Jack Lee, J, Hong, WK, Tang, X, Girard, L, Minna, JD, Diao, L, Wang, J, Mino, B, Villalobos, P, Rodriguez-Canales, J, Hanson, NE, Sun, J, Miller, V, Greenbowe, J, Frampton, G, Herbst, RS, Baladandayuthapani, V, Wistuba, II & Izzo, JG 2018, 'Concomitant targeting of the mTOR/MAPK pathways: Novel therapeutic strategy in subsets of RICTOR/KRAS-altered non-small cell lung cancer', Oncotarget, vol. 9, no. 74, pp. 33995-34008.
Ruder D, Papadimitrakopoulou V, Shien K, Behrens C, Kalhor N, Chen H et al. Concomitant targeting of the mTOR/MAPK pathways: Novel therapeutic strategy in subsets of RICTOR/KRAS-altered non-small cell lung cancer. Oncotarget. 2018 Sep 1;9(74):33995-34008.
Ruder, Dennis ; Papadimitrakopoulou, Vassiliki ; Shien, Kazuhiko ; Behrens, Carmen ; Kalhor, Neda ; Chen, Huiqin ; Shen, Li ; Jack Lee, J. ; Hong, Waun Ki ; Tang, Ximing ; Girard, Luc ; Minna, John D. ; Diao, Lixia ; Wang, Jing ; Mino, Barbara ; Villalobos, Pamela ; Rodriguez-Canales, Jaime ; Hanson, Nana E. ; Sun, James ; Miller, Vincent ; Greenbowe, Joel ; Frampton, Garrett ; Herbst, Roy S. ; Baladandayuthapani, Veera ; Wistuba, Ignacio I. ; Izzo, Julie G. / Concomitant targeting of the mTOR/MAPK pathways : Novel therapeutic strategy in subsets of RICTOR/KRAS-altered non-small cell lung cancer. In: Oncotarget. 2018 ; Vol. 9, No. 74. pp. 33995-34008.
@article{37ef7ea4c91b4f47bf48b5d692db92e2,
title = "Concomitant targeting of the mTOR/MAPK pathways: Novel therapeutic strategy in subsets of RICTOR/KRAS-altered non-small cell lung cancer",
abstract = "Despite a therapeutic paradigm shift into targeted-driven medicinal approaches, resistance to therapy remains a hallmark of lung cancer, driven by biological and molecular diversity. Using genomic and expression data from advanced non-small cell lung cancer (NSCLC) patients enrolled in the BATTLE-2 clinical trial, we identified RICTOR alterations in a subset of lung adenocarcinomas and found RICTOR expression to carry worse overall survival. RICTOR-altered cohort was significantly enriched in KRAS/MAPK axis mutations, suggesting a co-oncogenic driver role in these molecular settings. Using NSCLC cell lines, we showed that, distinctly in KRAS mutant backgrounds, RICTOR blockade impairs malignant properties and generates a compensatory enhanced activation of the MAPK pathway, exposing a unique therapeutic vulnerability. In vitro and in vivo concomitant pharmacologic inhibition of mTORC1/2 and MEK1/2 resulted in synergistic responses of anti-tumor effects. Our study provides evidence of a distinctive therapeutic opportunity in a subset of NSCLC carrying concomitant RICTOR/KRAS alterations.",
keywords = "KRAS mutation, MAPK pathway, MTORC2, Non-small cell lung cancer, RICTOR gene abnormalities",
author = "Dennis Ruder and Vassiliki Papadimitrakopoulou and Kazuhiko Shien and Carmen Behrens and Neda Kalhor and Huiqin Chen and Li Shen and {Jack Lee}, J. and Hong, {Waun Ki} and Ximing Tang and Luc Girard and Minna, {John D.} and Lixia Diao and Jing Wang and Barbara Mino and Pamela Villalobos and Jaime Rodriguez-Canales and Hanson, {Nana E.} and James Sun and Vincent Miller and Joel Greenbowe and Garrett Frampton and Herbst, {Roy S.} and Veera Baladandayuthapani and Wistuba, {Ignacio I.} and Izzo, {Julie G.}",
year = "2018",
month = "9",
day = "1",
language = "English",
volume = "9",
pages = "33995--34008",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "74",

}

TY - JOUR

T1 - Concomitant targeting of the mTOR/MAPK pathways

T2 - Novel therapeutic strategy in subsets of RICTOR/KRAS-altered non-small cell lung cancer

AU - Ruder, Dennis

AU - Papadimitrakopoulou, Vassiliki

AU - Shien, Kazuhiko

AU - Behrens, Carmen

AU - Kalhor, Neda

AU - Chen, Huiqin

AU - Shen, Li

AU - Jack Lee, J.

AU - Hong, Waun Ki

AU - Tang, Ximing

AU - Girard, Luc

AU - Minna, John D.

AU - Diao, Lixia

AU - Wang, Jing

AU - Mino, Barbara

AU - Villalobos, Pamela

AU - Rodriguez-Canales, Jaime

AU - Hanson, Nana E.

AU - Sun, James

AU - Miller, Vincent

AU - Greenbowe, Joel

AU - Frampton, Garrett

AU - Herbst, Roy S.

AU - Baladandayuthapani, Veera

AU - Wistuba, Ignacio I.

AU - Izzo, Julie G.

PY - 2018/9/1

Y1 - 2018/9/1

N2 - Despite a therapeutic paradigm shift into targeted-driven medicinal approaches, resistance to therapy remains a hallmark of lung cancer, driven by biological and molecular diversity. Using genomic and expression data from advanced non-small cell lung cancer (NSCLC) patients enrolled in the BATTLE-2 clinical trial, we identified RICTOR alterations in a subset of lung adenocarcinomas and found RICTOR expression to carry worse overall survival. RICTOR-altered cohort was significantly enriched in KRAS/MAPK axis mutations, suggesting a co-oncogenic driver role in these molecular settings. Using NSCLC cell lines, we showed that, distinctly in KRAS mutant backgrounds, RICTOR blockade impairs malignant properties and generates a compensatory enhanced activation of the MAPK pathway, exposing a unique therapeutic vulnerability. In vitro and in vivo concomitant pharmacologic inhibition of mTORC1/2 and MEK1/2 resulted in synergistic responses of anti-tumor effects. Our study provides evidence of a distinctive therapeutic opportunity in a subset of NSCLC carrying concomitant RICTOR/KRAS alterations.

AB - Despite a therapeutic paradigm shift into targeted-driven medicinal approaches, resistance to therapy remains a hallmark of lung cancer, driven by biological and molecular diversity. Using genomic and expression data from advanced non-small cell lung cancer (NSCLC) patients enrolled in the BATTLE-2 clinical trial, we identified RICTOR alterations in a subset of lung adenocarcinomas and found RICTOR expression to carry worse overall survival. RICTOR-altered cohort was significantly enriched in KRAS/MAPK axis mutations, suggesting a co-oncogenic driver role in these molecular settings. Using NSCLC cell lines, we showed that, distinctly in KRAS mutant backgrounds, RICTOR blockade impairs malignant properties and generates a compensatory enhanced activation of the MAPK pathway, exposing a unique therapeutic vulnerability. In vitro and in vivo concomitant pharmacologic inhibition of mTORC1/2 and MEK1/2 resulted in synergistic responses of anti-tumor effects. Our study provides evidence of a distinctive therapeutic opportunity in a subset of NSCLC carrying concomitant RICTOR/KRAS alterations.

KW - KRAS mutation

KW - MAPK pathway

KW - MTORC2

KW - Non-small cell lung cancer

KW - RICTOR gene abnormalities

UR - http://www.scopus.com/inward/record.url?scp=85053815762&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85053815762&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:85053815762

VL - 9

SP - 33995

EP - 34008

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 74

ER -